Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis

Valiyeva, Elmira; Herrmann, Nathan; Rochon, Paula A.; Gill, Sudeep S.; Anderson, Geoffrey M.
August 2008
CMAJ: Canadian Medical Association Journal;8/26/2008, Vol. 179 Issue 5, p438
Academic Journal
Background: Three warnings of serious adverse events associated with the use of atypical antipsychotic drugs among elderly patients with dementia were sent to health care professionals in Canada. We assessed the impact of these warnings on prescription rates of antipsychotic drugs in this patient population. Methods: We used prescription drug claims data from Ontario to calculate prescription rates of atypical and conventional antipsychotic drugs among elderly patients with dementia from May 1, 2000, to Feb. 28, 2007. We performed a time-series analysis to estimate the effect of each warning on rates of antipsychotic drug use. Results: Before the first warning, growth in the use of atypical antipsychotics was responsible for an increasing rate of overall antipsychotic use. Each warning was associated with a small relative decrease in the predicted growth in the use of atypical antipsychotic drugs: a 5.0% decrease after the first warning, 4.9% after the second and 3.2% after the third (each p < 0.05). The overall prescription rate of antipsychotic drugs among patients with dementia increased by 20%, from 1512 per 100 000 elderly patients in September 2002, the month before the first warning, to 1813 per 100 000 in February 2007, 20 months after the last warning. Interpretation: Although the warnings slowed the growth in the use of atypical antipsychotic drugs among patients with dementia, they did not reduce the overall prescription rate of these potentially dangerous drugs. More effective interventions are necessary to improve postmarket drug safety in vulnerable populations.


Related Articles

  • Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia. Maust, Donovan T.; Hyungjin Myra Kim; Seyfried, Lisa S.; Chiang, Claire; Kavanagh, Janet; Schneider, Lon S.; Kales, Helen C. // JAMA Psychiatry;May2015, Vol. 72 Issue 5, p438 

    IMPORTANE Antipsychotic medications are associated with increased mortality in older adults with dementia, yet their absolute effect on risk relative to no treatment or an alternative psychotropic is unclear. OBJECTIVE To determine the absolute mortality risk increase and number needed to harm...

  • The burden of psychotropic drug prescribingin people with dementia: a populationdatabase study. Guthrie, Bruce; Clark, Stella Anne; McCowan, Colin // Age & Ageing;Sep2010, Vol. 39 Issue 5, p637 

    Objective: to compare psychotropic prescribing in older people with dementia and the general elderly population. Design and setting: retrospective population database study in 315 General Practices. Subjects: there were 271,365 patients aged ⩾65, of which 10,058 (3.7%) recorded as having...

  • Exclusive: GPs are urged to review dementia prescribing. Robinson, Stephen // GP: General Practitioner;6/10/2011, p7 

    The article reports that the Dementia Action Alliance (DAA) has urged general practitioners (GPs) to review the prescriptions of dementia patients within the next nine months in Great Britain. The DAA is a group of 50 organisations including the Royal College of General Practitioners (RCGP), the...

  • Death risk drugs.  // Mental Health Today;Jun2005, p7 

    Reports on the research findings of the Alzheimer's Society as of 2005, that potentially fatal neuroleptic drugs are still being prescribed to elderly people with dementia after being banned in Great Britain in 2004. Information on the rule of the Committee on Safety of Medicines, banning...

  • Involving the Resident/Decision Maker in Antipsychotic Medication Use. Mort, Jane R. // South Dakota Medicine;Apr2013, Vol. 66 Issue 4, p148 

    The article examines the importance of involving nursing home residents/residents' decision makers in the potential use of antipsychotic medications. Topics discussed include the standards that may be used in examining the appropriateness of prescribing antipsychotic agents, the common...

  • Call to cut dementia drugs.  // Pulse;3/9/2011, Vol. 71 Issue 9, p11 

    The article reports on the call to cut the number of antipsychotic drugs prescribed for patients with dementia in Great Britain.

  • News in brief ...  // PharmacoEconomics & Outcomes News;7/16/2005, Issue 482, p8 

    Presents the results of a study regarding the link between the use of antipsychotics or concomitant use of psychotropics with an increased mortality rate in elderly patients with dementia. Reference to a study by S. Hartikainen et al published in a July 2005 issue of "International Clinical...

  • QOF could cut antipsychotic use for dementia patients. Robinson, Stephen // GP: General Practitioner;2/1/2012, p14 

    The article reports that according to a research, antipsychotic prescribing for dementia need to be reviewed as part of the qality and outcomes famework (QOF) to slash inappropriate use of the drugs. The study found that of patients with dementia were prescribed antipsychotics despite high rates...

  • Drug review warns on use of antipsychotics. Baines, Emma // GP: General Practitioner;3/15/2004, p14 

    The Medicines and Healthcare Products Regulatory Agency (MHRA) has warned that the atypical antipsychotics risperidone and olanzapine should not be used to treat behavioral problems in elderly patients with dementia. The advice comes in the light of a drug safety review carried out by the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics